CD146 is a coreceptor for VEGFR-2 in tumor angiogenesis

被引:217
作者
Jiang, Tianxia [1 ]
Zhuang, Jie [1 ]
Duan, Hongxia [1 ]
Luo, Yongting [1 ]
Zeng, Qiqun [1 ]
Fan, Kelong [1 ]
Yan, Huiwen [1 ]
Lu, Di [1 ]
Ye, Zhongde [1 ]
Hao, Junfeng [1 ]
Feng, Jing [1 ]
Yang, Dongling [1 ]
Yan, Xiyun [1 ]
机构
[1] Chinese Acad Sci, Inst Biophys, Chinese Acad Sci Univ Tokyo Joint Lab Struct Viro, Natl Lab Biomacromol,Key Lab Prot & Peptide Pharm, Beijing 100101, Peoples R China
基金
中国国家自然科学基金;
关键词
ENDOTHELIAL GROWTH-FACTOR; CELL-ADHESION MOLECULE; PHASE-III TRIAL; ANTI-CD146; MONOCLONAL-ANTIBODY; INHIBITS ANGIOGENESIS; BREAST-CANCER; BEVACIZUMAB; MIGRATION; CD44; EXPRESSION;
D O I
10.1182/blood-2012-01-406108
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
CD146 is a novel endothelial biomarker and plays an essential role in angiogenesis; however, its role in the molecular mechanism underlying angiogenesis remains poorly understood. In the present study, we show that CD146 interacts directly with VEGFR-2 on endothelial cells and at the molecular level and identify the structural basis of CD146 binding to VEGFR-2. In addition, we show that CD146 is required in VEGF-induced VEGFR-2 phosphorylation, AKT/p38 MAPKs/NF-kappa B activation, and thus promotion of endothelial cell migration and microvascular formation. Furthermore, we show that anti-CD146 AA98 or CD146 siRNA abrogates all VEGFR-2 activation induced by VEGF. An in vivo angiogenesis assay showed that VEGF-promoted microvascular formation was impaired in the endothelial conditional knockout of CD146 (CD146(EC-KO)). Our animal experiments demonstrated that anti-CD146 (AA98) and anti-VEGF (bevacizumab) have an additive inhibitory effect on xenografted human pancreatic and melanoma tumors. The results of the present study suggest that CD146 is a new coreceptor for VEGFR-2 and is therefore a promising target for blocking tumor-related angiogenesis. (Blood. 2012;120(11):2330-2339)
引用
收藏
页码:2330 / 2339
页数:10
相关论文
共 48 条
[1]
Involvement of gicerin, a cell adhesion molecule, in the portal metastasis of rat colorectal adenocarcinoma cells [J].
Adachi, Kazuhide ;
Hattori, Mahiro ;
Kato, Hidenori ;
Inai, Marie ;
Tsukamoto, Masaya ;
Handharyani, Ekowati ;
Taira, Eiichi ;
Tsukamoto, Yasuhiro .
ONCOLOGY REPORTS, 2010, 24 (06) :1427-1431
[2]
M-cam expression as marker of poor prognosis in epithelial ovarian cancer [J].
Aldovini, Daniela ;
Demichelis, Francesca ;
Doglioni, Claudio ;
Di Vizio, Dolores ;
Galligioni, Enzo ;
Brugnara, Sonia ;
Zeni, Bruna ;
Griso, Claudia ;
Pegoraro, Cristina ;
Zannoni, Marina ;
Gariboldi, Manuela ;
Balladore, Emanuela ;
Mezzanzanica, Delia ;
Canevari, Silvana ;
Barbareschi, Mattia .
INTERNATIONAL JOURNAL OF CANCER, 2006, 119 (08) :1920-1926
[3]
Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08 [J].
Allegra, Carmen J. ;
Yothers, Greg ;
O'Connell, Michael J. ;
Sharif, Saima ;
Petrelli, Nicholas J. ;
Colangelo, Linda H. ;
Atkins, James N. ;
Seay, Thomas E. ;
Fehrenbacher, Louis ;
Goldberg, Richard M. ;
O'Reilly, Seamus ;
Chu, Luis ;
Azar, Catherine A. ;
Lopa, Samia ;
Wolmark, Norman .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (01) :11-16
[4]
Activation of human endothelial cells via S-endo-1 antigen (CD146) stimulates the tyrosine phosphorylation of focal adhesion kinase p125FAK [J].
Anfosso, F ;
Bardin, N ;
Francès, V ;
Vivier, E ;
Camoin-Jau, L ;
Sampol, J ;
Dignat-George, F .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (41) :26852-26856
[5]
Outside-in signaling pathway linked to CD146 engagement in human endothelial cells [J].
Anfosso, F ;
Bardin, N ;
Vivier, E ;
Sabatier, F ;
Sampol, J ;
Dignat-George, F .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (02) :1564-1569
[6]
[Anonymous], 2002, Drugs R D, V3, P28
[7]
Visualization of CD146 dimerization and its regulation in living cells [J].
Bu, Pengcheng ;
Zhuang, Jie ;
Feng, Jing ;
Yang, Dongling ;
Shen, Xun ;
Yan, Xiyun .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2007, 1773 (04) :513-520
[8]
Anti-CD146 monoclonal antibody AA98 inhibits angiogenesis via suppression of nuclear factor-κB activation [J].
Bu, Pengcheng ;
Gao, Lizeng ;
Zhuang, Jie ;
Feng, Jing ;
Yang, Dongling ;
Yan, Xiyun .
MOLECULAR CANCER THERAPEUTICS, 2006, 5 (11) :2872-2878
[9]
Molecular mechanisms and clinical applications of angiogenesis [J].
Carmeliet, Peter ;
Jain, Rakesh K. .
NATURE, 2011, 473 (7347) :298-307
[10]
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial [J].
Escudier, Bernard ;
Pluzanska, Anna ;
Koralewski, Piotr ;
Ravaud, Alain ;
Bracarda, Sergio ;
Szczylik, Cezary ;
Chevreau, Christine ;
Filipek, Marek ;
Melichar, Bohuslav ;
Bajetta, Emilio ;
Gorbunova, Vera ;
Bay, Jacques-Olivier ;
Bodrogi, Istvan ;
Jagiello-Gruszfeld, Agnieszka ;
Moore, Nicola .
LANCET, 2007, 370 (9605) :2103-2111